Similarly, MRX-2843, a dual MerTK/Axl inhibitor, has shown immune-modulatory activity in acute myeloid leukemia (AML), lung adenocarcinoma, ovarian cancer, and pediatric gliomas, where it reprogrammed tumor-associated macrophages and improved T cell function (127). Here, MERTK is linked to ovarian cancer.